Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul, Korea.
Cell Prolif. 2020 May;53(5):e12819. doi: 10.1111/cpr.12819. Epub 2020 May 5.
The objective of this study was to explore characteristics of bone marrow mesenchymal stromal cells (BM-MSCs) derived from patients with myelodysplastic syndrome (MDS) and multiple myeloma (MM).
BM-MSCs were recovered from 17 of MDS patients, 23 of MM patients and 9 healthy donors and were passaged until proliferation stopped. General characteristics and gene expression profiles of MSCs were analysed. In vitro, ex vivo coculture, immunohistochemistry and knockdown experiments were performed to verify gene expression changes.
BM-MSCs failed to culture in 35.0% of patients and 50.0% of recovered BM-MSCs stopped to proliferate before passage 6. MDS- and MM-MSCs shared characteristics including decreased osteogenesis, increased angiogenesis and senescence-associated molecular pathways. In vitro and ex vivo experiments showed disease-specific changes such as neurogenic tendency in MDS-MSCs and cardiomyogenic tendency in MM-MSCs. Although the age of normal control was younger than patients and telomere length was shorter in patient's BM-MSCs, they were not different according to disease category nor degree of proliferation. Specifically, poorly proliferation BM-MSCs showed CDKN2A overexpression and CXCL12 downregulation. Immunohistochemistry of BM biopsy demonstrated that CDKN2A was intensely accumulation in perivascular BM-MSCs failed to culture. Interestingly, patient's BM-MSCs revealed improved proliferation activity after CDKN2A knockdown.
These results collectively indicate that MDS-MSCs and MM-MSCs have common and different alterations at various degrees. Hence, it is necessary to evaluate their alteration status using representative markers such as CDKN2A expression.
本研究旨在探讨骨髓间充质基质细胞(BM-MSCs)来源于骨髓增生异常综合征(MDS)和多发性骨髓瘤(MM)患者的特征。
从 17 例 MDS 患者、23 例 MM 患者和 9 名健康供体中回收 BM-MSCs,并传代至增殖停止。分析 MSCs 的一般特征和基因表达谱。体外、离体共培养、免疫组织化学和基因敲低实验验证基因表达变化。
35.0%的患者和 50.0%的回收 BM-MSCs 在培养过程中失败,在传代 6 代前停止增殖。MDS 和 MM-MSCs 具有共同的特征,包括成骨能力下降、血管生成增加和衰老相关的分子途径。体外和离体实验显示 MDS-MSCs 具有神经发生倾向,MM-MSCs 具有心肌发生倾向等疾病特异性变化。尽管正常对照组的年龄小于患者,且患者 BM-MSCs 的端粒长度较短,但根据疾病类别和增殖程度,它们没有差异。具体而言,增殖不良的 BM-MSCs 表现出 CDKN2A 过表达和 CXCL12 下调。BM 活检的免疫组织化学显示,未能培养的血管周围 BM-MSCs 中 CDKN2A 强烈积聚。有趣的是,患者的 BM-MSCs 在 CDKN2A 敲低后表现出增殖活性的改善。
这些结果共同表明,MDS-MSCs 和 MM-MSCs 在不同程度上具有共同和不同的改变。因此,有必要使用 CDKN2A 表达等代表性标志物评估其改变状态。